Introduction
In the ever-evolving realm of oncological treatment, scientists persistently seek out unconventional targets that can amplify the effectiveness of interventions while mitigating unwanted...
bcma
March 2022: After four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, the Food and Drug Administration ...
bcma